Arden House Medicare and Medicaid Location: 850 Mix Ave, Hamden, Connecticut 06514 Ratings: Phone: (203) 281-3500 |
Whitney Rehabilitation Care Center Medicare and Medicaid Location: 2798 Whitney Avenue, Hamden, Connecticut 06518 Ratings: Phone: (203) 288-6230 |
Whitney Center Medicare and Medicaid Location: 200 Leeder Hill Dr, Hamden, Connecticut 06517 Ratings: Phone: (203) 281-6745 |
Hamden Rehabilitation & Health Care Center Medicare and Medicaid Location: 1270 Sherman Lane, Hamden, Connecticut 06514 Ratings: Phone: (203) 281-7555 |
News Archive
Now, new research published in the journal Hippokratia focuses on assisting the ongoing COVID-19 therapeutic research by developing a new method to identify active compounds that have the potential to fight against COVID-19 infection.
World Heart Corporation (WorldHeart) announced today that it has finalized assignment and exclusive license agreements with LaunchPoint Technologies Inc., (LPT) Goleta, California, and Carnegie Mellon University (CMU), Pittsburgh, Pennsylvania for its next-generation minimally invasive blood pump, the MiVAD. The MiVAD(TM) is designed to provide partial cardiac support between 2-4 liters per minute to less sick heart failure patients than those served by existing full-support Left Ventricular Assist Devices (LVADs).
Preemies between 28 and 32 weeks are not harmed by a treatment no longer used to help their lungs mature before birth, according to findings of a study in this month's Pediatrics.
It is known that HIV-infected children who do not receive appropriate antiretroviral drugs experience immune depression, and may become susceptible to infectious diseases that would otherwise be prevented by childhood immunization.
Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.
› Verified 1 days ago